Clinical Trials Browser

Completed × Surgical Procedures, Operative × 90 days × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT02364557 2026-05-19

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Phase 2/3 Completed

129 enrolled 23 charts

Breast

Breast Neoplasms, Lymphatic Metastasis

NCT02296684 2026-05-08

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

67 enrolled 15 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01872221 2026-04-14

STEMRI

Phase NA Completed

21 enrolled

CNS

Glioblastoma

NCT02676349 2026-03-27

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

Phase 2 Completed

130 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05577416 2026-03-18

AB-218-IIT-201

Phase EARLY_PHASE1 Completed

14 enrolled

CNS

Astrocytoma, Glioma, Oligodendroglioma

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00911911 2026-03-13

SPAM

Phase NA Completed

66 enrolled

Breast

Breast Neoplasms

Clinical Trials

KEYNOTE-866

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

STEMRI

Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

AB-218-IIT-201

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

SPAM